On VRTX's first-quarter earnings call, investors are likely to focus on the launch preparation for Alyftrek (vanza triple) ...

Iovance Biotherapeutics ( IOVA -1.52%) and CRISPR Therapeutics ( CRSP -1.27%) are two incredibly innovative biotechs, but this hasn't translated into strong performances recently. Both stocks have ...

On CRSP's first-quarter 2025 earnings call, investors will likely focus on the sales numbers of its new gene therapy, Casgevy.

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...

CRISPR Therapeutics’ top line currently includes grants and collaboration revenues from its partnership with large-cap biotech Vertex Pharmaceuticals VRTX. CRSP and partner VRTX’s one-shot ...

The National Academy of Sciences announced today the election of 120 members and 30 international members in recognition of ...

The market expects Entrada Therapeutics, Inc. (TRDA) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known ...

Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

Vertex Pharmaceuticals is expected to outshine projections when it reports Q1 2025 earnings, with strong sales from its ...